CN Patent

CN121398851A — Nmda配体缀合的化合物及其用途

Assigned to Adalx Pharmaceutical Co ltd · Expires 2026-01-23 · 0y expired

What this patent protects

本文提供了含有 N‑ 甲基‑D‑天冬氨酸(NMDA)受体配体的化合物，递送所述化合物的方法以及使用所述化合物治疗受试者的疾病、病症和症状(例如，中枢神经系统疾病、病症和症状)的方法。

USPTO Abstract

本文提供了含有 N‑ 甲基‑D‑天冬氨酸(NMDA)受体配体的化合物，递送所述化合物的方法以及使用所述化合物治疗受试者的疾病、病症和症状(例如，中枢神经系统疾病、病症和症状)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121398851A
Jurisdiction
CN
Classification
—
Expires
2026-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Adalx Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.